Microstirring Pill Enhances Drug Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The harsh gastric environment, primarily due to gastric acid, poses a barrier for the effective delivery of protein-based drugs and some antibiotics, leading to low bioavailability and adverse side effects from long-term use of proton pump inhibitors (PPIs).
Innovation Solution
A microstirring pill technology with embedded microstirrers that create a local fluid transport upon interaction with biological fluids, enhancing the distribution and absorption of therapeutic payloads by dissolving in gastric or intestinal fluids, thereby accelerating drug release and bioavailability without the adverse effects of PPIs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If proton pump inhibitors (PPIs) are used to reduce gastric acid production, then drug bioavailability is improved, but adverse side effects increase
Solution Approach 1:
The invention extracts the harmful gastric acid from the system by using localized neutralizing agents (antacids) that are delivered directly to the stomach lumen, rather than systemically suppressing acid production with PPIs. This approach neutralizes acid only where needed without causing the systemic side effects associated with long-term PPI use.
Solution Approach 2:
The invention introduces an intermediary substance (antacid formulation) that mediates between the drug and gastric acid. The antacid acts as a buffer that temporarily neutralizes gastric acid in the stomach lumen, creating a more favorable environment for drug absorption without requiring systemic acid suppression.
2Ease of operation
If drugs are administered orally in the presence of gastric acid, then ease of administration is improved, but drug degradation increases
Solution Approach 1:
The invention applies preliminary action by pre-formulating the drug with antacid agents in a single oral dosage form. This ensures that the antacid is already positioned to neutralize gastric acid before the drug encounters it, providing immediate protection against acid degradation upon administration.
Solution Approach 2:
The invention uses composite materials by combining the drug substance with antacid excipients (such as calcium carbonate, magnesium hydroxide, or aluminum hydroxide) in a unified oral formulation. This composite structure allows the antacid to protect the drug from gastric acid while maintaining ease of oral administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microstirring pill technology significantly enhances the bioavailability of drugs like aspirin and acetaminophen, demonstrating faster absorption and higher serum concentrations, with translational potential for various therapeutic cargoes, including peptides and proteins, by decoupling drug loading from microstirrer excipients, thus avoiding side effects associated with PPIs.
Implementation Method 1
microstirrers embedded in the pill matrix and configured to create a local fluid transport upon interacting with a biological fluid surrounding the microstirring pill
Implementation Method 2
micromotor particles dispersed within the pill matrix and operable to create a stirring effect within the fluid medium upon dissolution of the pill matrix
Implementation Method 3
pill matrix dissolvable in a fluid medium and loaded with a plurality of drug payloads
Data Source
AI summary
Disclosed are methods, materials and devices that pertain to a microstirring pill technology with built-in mixing capability for oral drug delivery that greatly enhances bioavailability of its therapeutic payload. In some aspects, a drug delivery device includes a pill matrix dissolvable in a fluid medium and loaded with a plurality of drug payloads; and a plurality of micro stirrers embedded in the pill matrix and configured to create a local fluid transport upon interacting with a biological fluid surrounding the microstirring pill.